Jaye Pf Chin‐Dusting
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jaye Pf Chin‐Dusting has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Ngan Ngoc Huynh
Vascular Pharmacology, Baker Heart Research Institute, Melbourne, Victoria, Australia
1 shared publicationPeter Angus
Liver Clinic, Austin and Repatriation Hospital and
1 shared publicationSamuel Battaglia
Liver Clinic, Austin and Repatriation Hospital, Melbourne, Victoria, Australia
1 shared publication
Latest Publications
- 16 June 2006
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 21 (7) , 1189-1193
Role of the endothelium on vasoactive agents in patients with liver cirrhosis
Background and Aim: Patients with liver cirrhosis exhibit peripheral vasodilatation and decreased vasoconstrictor responsiveness. We investigated the role of the endothelium in these patients.Methods: Nine patients with cirrhosis and seven controls were recruited. Responses to acetylcholine, bradykinin and sodium nitroprusside were obtained using forearm plethysmography. Responses to norepinephrine (100 ng/min) were obtained in the absence and combined presence of the cyclo‐oxygenase inhibitor, indomethacin, and the nitric oxide (NO) synthase inhibitor, NG‐monomethyl‐L‐arginine.Results: Responses to acetylcholine (area under curve: controls vs cirrhotic, 10326 ± 1400 vs 18490 ± 2787 units; P = 0.036), but not to bradykinin (15619 ± 3557 vs 12415 ± 3823 units) or sodium nitroprusside, were significantly higher in patients with cirrhosis. Responses to norepinephrine were significantly dampened in cirrhotics (percentage increase in forearm blood flow; controls vs cirrhotics, −50.50 ± 2.69 vs−26.39 ± 5.44; P = 0.036) but this blunted response was no longer apparent following the administration of both blockers.Conclusions: We conclude that: (i) there is an increased response to acetylcholine but not to bradykinin; and (ii) that an enhanced production of prostacyclin and/or NO is responsible for the dampened response to norepinephrine.
- 16 June 2006
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 21 (7) , 1189-1193
Role of the endothelium on vasoactive agents in patients with liver cirrhosis
Background and Aim: Patients with liver cirrhosis exhibit peripheral vasodilatation and decreased vasoconstrictor responsiveness. We investigated the role of the endothelium in these patients.Methods: Nine patients with cirrhosis and seven controls were recruited. Responses to acetylcholine, bradykinin and sodium nitroprusside were obtained using forearm plethysmography. Responses to norepinephrine (100 ng/min) were obtained in the absence and combined presence of the cyclo‐oxygenase inhibitor, indomethacin, and the nitric oxide (NO) synthase inhibitor, NG‐monomethyl‐L‐arginine.Results: Responses to acetylcholine (area under curve: controls vs cirrhotic, 10326 ± 1400 vs 18490 ± 2787 units; P = 0.036), but not to bradykinin (15619 ± 3557 vs 12415 ± 3823 units) or sodium nitroprusside, were significantly higher in patients with cirrhosis. Responses to norepinephrine were significantly dampened in cirrhotics (percentage increase in forearm blood flow; controls vs cirrhotics, −50.50 ± 2.69 vs−26.39 ± 5.44; P = 0.036) but this blunted response was no longer apparent following the administration of both blockers.Conclusions: We conclude that: (i) there is an increased response to acetylcholine but not to bradykinin; and (ii) that an enhanced production of prostacyclin and/or NO is responsible for the dampened response to norepinephrine.
- 26 January 2006
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 33 (1-2) , 1-8
AMINO ACIDS, ARGINASE AND NITRIC OXIDE IN VASCULAR HEALTH
1. Nitric oxide (NO) plays a fundamental role in the vasculature because of its diverse influence in vascular protection, including its well-reported antiproliferative, anti-inflammatory, antithrombotic and vasodilator effects. In many vascular disease states, NO production is reduced as a result of endothelial dysfunction, in part caused by a decrease in substrate (L-arginine) availability. 2. The role of L-arginine and other amino acids important in nitrogen balance has been re-examined in the context of their effects on vascular health. The metabolism of L-arginine is complex because it is involved in a plethora of other pathways, such as urea, creatine and agmatine production. L-Arginine supplementation in patients with vascular disease is well reported to benefit patients therapeutically because of its effect on both NO-dependent and -independent mechanisms. 3. L-Arginine availability depends on the flux of other amino acids in the body, including L-glutamine, L-glutamate, L-ornithine, L-citrulline and L-lysine. The role of L-methionine and homocystine and their effect on NO also play an influential role in the body. 4. Recent data suggest that the key enzyme involved in the L-arginine-urea cycle, arginase, is coexpressed in NO-producing cells in the vasculature. In the present review, we examine the potential role of arginase as a therapeutic target for vascular health.
- 26 January 2006
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 33 (1-2) , 1-8
AMINO ACIDS, ARGINASE AND NITRIC OXIDE IN VASCULAR HEALTH
1. Nitric oxide (NO) plays a fundamental role in the vasculature because of its diverse influence in vascular protection, including its well-reported antiproliferative, anti-inflammatory, antithrombotic and vasodilator effects. In many vascular disease states, NO production is reduced as a result of endothelial dysfunction, in part caused by a decrease in substrate (L-arginine) availability. 2. The role of L-arginine and other amino acids important in nitrogen balance has been re-examined in the context of their effects on vascular health. The metabolism of L-arginine is complex because it is involved in a plethora of other pathways, such as urea, creatine and agmatine production. L-Arginine supplementation in patients with vascular disease is well reported to benefit patients therapeutically because of its effect on both NO-dependent and -independent mechanisms. 3. L-Arginine availability depends on the flux of other amino acids in the body, including L-glutamine, L-glutamate, L-ornithine, L-citrulline and L-lysine. The role of L-methionine and homocystine and their effect on NO also play an influential role in the body. 4. Recent data suggest that the key enzyme involved in the L-arginine-urea cycle, arginase, is coexpressed in NO-producing cells in the vasculature. In the present review, we examine the potential role of arginase as a therapeutic target for vascular health.